TABLE 1.
Patient Characteristics
| Characteristic | Variable | Data | % |
|---|---|---|---|
| Total patients | 54 | 100 | |
| Sex | Male | 45 | 83.3 |
| Female | 9 | 16.7 | |
| Age | |||
| Mean | 67.1 | ||
| Range | 48–84 | ||
| PS | 0 | 51 | 94.4 |
| 1 | 3 | 5.6 | |
| Smoking | Never smokers | 8 | 14.8 |
| Former smokers | 24 | 44.4 | |
| Current smokers | 22 | 40.7 | |
| Pack years | |||
| Mean | 36.7 | ||
| Range | 0–150 | ||
| Primary site | Oral cavity | 3 | 5.6 |
| Rhinopharynx | 2 | 3.7 | |
| Oropharynx | 33 | 61.1 | |
| Hypopharynx | 8 | 14.8 | |
| Larynx | 8 | 14.8 | |
| P16 (oropharynx) | p16-positive | 26 | 78.7 |
| p16-negative | 7 | 21.2 | |
| EBV-positive | 1 | 1.9 | |
| Stage* | I | 12 | 22.2 |
| II | 20 | 37.0 | |
| III | 9 | 16.7 | |
| IV | 13 | 24.1 | |
| T classification | T1 | 4 | 7.4 |
| T2 | 26 | 48.1 | |
| T3 | 13 | 24.1 | |
| T4 | 11 | 20.4 | |
| N classification | N0 | 21 | 38.9 |
| N1 | 14 | 25.9 | |
| N2 | 19 | 35.2 | |
| Chemotherapy | No cisplatin | 25 | 46.3 |
| Cisplatin | 29 | 53.7 | |
| Nimorazole | No | 5 | 9.3 |
| Yes | 49 | 90.7 |
*
According to Union for International Cancer Control classification, eighth edition.
PS = performance status; EBV = Epstein–Barr virus.
Qualitative data are number and percentage; continuous data are mean and range.